Cor pulmonale is right ventricular (RV) enlargement (hypertrophy and/or dilatation) secondary to pulmonary hypertension caused by diseases of the lung parenchyma, pulmonary vasculature, or ventilatory drive — independent of left heart disease. [1-3] It may present acutely (e.g., massive PE) or chronically (e.g., COPD, interstitial lung disease). The primary mechanism is chronic alveolar hypoxia → pulmonary vasoconstriction → vascular remodeling → elevated RV afterload → RV failure. [4-5]
1. History
- Dyspnea — most common symptom; initially exertional, progressing to rest; characterize onset, duration, and trajectory [6-7]
- Lower-extremity edema — progressive, bilateral, pitting; worse at end of day
- Early satiety, abdominal fullness, RUQ tenderness — from hepatic congestion and ascites [6]
- Fatigue and exercise intolerance — often out of proportion to lung function impairment [8]
- Syncope or presyncope — especially exertional; suggests severely reduced cardiac output [7]
- Chest pain — may indicate RV ischemia from pressure overload
- Ask about timing of symptom worsening relative to pulmonary disease progression; suspect cor pulmonale when symptoms exceed what lung function data would predict [8]
- Important negatives: orthopnea and PND (more suggestive of left heart failure, though can overlap)
2. Alarm Features
- Exertional syncope — indicates critically reduced cardiac output [9]
- Hypotension or shock — acute RV failure with hemodynamic compromise [6][10]
- New or worsening hypoxemia refractory to supplemental O₂
- Rapid clinical deterioration not matched by decline in pulmonary function [8]
- Signs of cardiogenic shock: altered mental status, cool extremities, oliguria, rising lactate
- Acute massive PE causing acute cor pulmonale — sudden dyspnea, pleuritic chest pain, hemodynamic instability
- Abrupt discontinuation of pulmonary vasodilators in known PAH patients can precipitate fatal RV failure [9]
3. Medications
Common treatments
- Diuretics — loop diuretics (furosemide, bumetanide) for volume overload; thiazides for augmentation [6]
- Supplemental oxygen — the only therapy shown to improve survival in COPD-related cor pulmonale [2][4]
- PAH-specific therapies (Group 1 PH only): endothelin receptor antagonists (bosentan, ambrisentan, macitentan), PDE-5 inhibitors (sildenafil, tadalafil), prostacyclin analogues (epoprostenol, treprostinil), soluble guanylate cyclase stimulators (riociguat), sotatercept [6][11]
- Inhaled treprostinil — FDA-approved for Group 3 PH (ILD-associated) [6][11]
- Digoxin — may reduce symptoms in chronic RV failure; evidence is mixed [6]
- Inotropes/vasopressors for acute decompensation: dobutamine, milrinone, norepinephrine [6]
Medication cautions
- Calcium channel blockers — only for vasoreactive idiopathic PAH confirmed by catheterization; contraindicated in non-vasoreactive PH [6]
- Systemic vasodilators (CCBs, ACE inhibitors) in COPD-related cor pulmonale may worsen V/Q mismatch and lower PaO₂ [4]
- Pulmonary vasodilators are NOT beneficial (and may be harmful) in Group 2 PH (left heart disease) [6]
- Avoid excessive IV fluids — RV is preload-sensitive; volume overload worsens RV dilatation and septal shift [9-10]
- Avoid intubation if possible — positive pressure ventilation increases RV afterload [9-10]
4. Diet
- Sodium restriction (≤2 g/day) to minimize fluid retention
- Fluid restriction (typically 1.5–2 L/day) in patients with significant volume overload
- Adequate nutrition — cardiac cachexia is common in advanced RV failure; early satiety limits intake [6]
- Avoid excessive alcohol — cardiomyopathic effects
- Weight monitoring — daily weights to track fluid status
5. Review of Systems
- Cardiovascular: chest pain, palpitations, syncope, presyncope, orthopnea, PND
- Pulmonary: cough, wheezing, sputum production, hemoptysis, snoring/witnessed apneas (OSA)
- GI: early satiety, nausea, abdominal distension, RUQ pain (hepatic congestion)
- Neurologic: lightheadedness, confusion (low cardiac output)
- Musculoskeletal: exercise intolerance, fatigue
- Extremities: bilateral leg swelling, skin changes
- Constitutional: weight gain (fluid) or weight loss (cachexia), anorexia
6. Collateral History and Family History
- Family history of PAH — up to 20% of "idiopathic" PAH cases involve heritable mutations (BMPR2 most common) [6]
- Family history of sudden cardiac death, arrhythmogenic RV cardiomyopathy (ARVC), left heart failure [6]
- Connective tissue disease history (especially systemic sclerosis — high risk for PAH) [12]
- Social history: tobacco use (COPD risk), illicit drug use (methamphetamine → PAH), anorexigen use (fenfluramine) [6]
- Occupational exposures: asbestos, silica (ILD risk)
- HIV status, hepatitis, liver disease (portopulmonary hypertension) [7]
- Travel history: schistosomiasis-endemic areas [7]
- Sleep history from bed partner: snoring, apneas (OSA/OHS)
7. Risk Factors
- COPD — most common cause of chronic cor pulmonale; risk increases with hypoxemia, CO₂ retention, and severely reduced FEV₁ [4][13]
- Interstitial lung disease (IPF, combined pulmonary fibrosis and emphysema) [3][14]
- Obstructive sleep apnea / obesity hypoventilation syndrome [3][12]
- Chronic thromboembolic disease (recurrent PE → CTEPH) [7]
- Connective tissue diseases (systemic sclerosis, SLE) [12]
- HIV infection, portal hypertension, congenital heart disease [7][12]
- Chronic hypoxia (high altitude, neuromuscular disease, kyphoscoliosis) [3]
- Tobacco use, advanced age, polycythemia [4]
- Drug/toxin exposure: methamphetamine, anorexigens, dasatinib [12]
8. Differential Diagnosis
- Left heart failure (HFrEF or HFpEF) — most common cause of PH overall (Group 2); distinguished by elevated PAWP on RHC [7]
- Acute pulmonary embolism — acute cor pulmonale; sudden onset, consider Wells/PERC criteria
- Constrictive pericarditis — elevated JVP, Kussmaul sign; distinguished by pericardial thickening, septal bounce on echo [15]
- Restrictive cardiomyopathy (amyloid, sarcoid) — biatrial enlargement, diastolic dysfunction [15]
- Primary RV cardiomyopathy / ARVC — arrhythmias, fibrofatty RV replacement on MRI
- Cardiac tamponade — equalization of diastolic pressures, pulsus paradoxus
- Hepatic cirrhosis with ascites — may mimic RV failure; portopulmonary hypertension can coexist
- Nephrotic syndrome — peripheral edema from hypoalbuminemia
- Superior vena cava syndrome — elevated JVP without hepatic congestion
9. Past Medical History
- COPD, asthma, ILD, cystic fibrosis — underlying lung disease driving PH
- Prior VTE/PE — risk for CTEPH
- Connective tissue disease, HIV, chronic liver disease
- Congenital heart disease (ASD, VSD, Eisenmenger syndrome)
- Prior cardiac surgery or valve disease
- Sleep apnea — diagnosed or suspected
- Smoking history (pack-years)
- Previous echocardiograms or RHC — baseline RV function and PA pressures
10. Physical Exam
- Vital signs: tachycardia, tachypnea, hypoxemia (SpO₂ <90%), hypotension in severe cases
- JVP: elevated (most sensitive sign); prominent V wave (TR), prominent A wave (RV diastolic dysfunction), Kussmaul sign [16-17]
- Precordium: left parasternal heave (RV enlargement), loud P₂ (pulmonary hypertension) [6][16]
- Auscultation: holosystolic murmur at left lower sternal border increasing with inspiration (Carvallo sign = TR); pulmonic regurgitation murmur (Graham Steell murmur) [16]
- Abdomen: hepatomegaly (pulsatile if significant TR), hepatojugular reflux, ascites [6]
- Extremities: bilateral pitting edema, presacral edema, cyanosis [16]
- General: cachexia, cyanosis in advanced disease [16]
- The combination of JVP >3 cm, parasternal heave, and peripheral edema discriminates severe PH (AUC = 0.82) [17]
11. Lab Studies
- BNP / NT-proBNP — elevated in RV dysfunction; sensitive but not specific; useful for tracking disease trajectory [6][18]
- CBC — polycythemia (chronic hypoxemia); anemia (worsens symptoms)
- BMP — renal function (cardiorenal syndrome), electrolytes (diuretic effects)
- LFTs — congestive hepatopathy (elevated bilirubin, transaminases, INR)
- ABG — hypoxemia, hypercapnia, respiratory acidosis [2]
- Troponin — RV ischemia/strain
- Lactate — tissue hypoperfusion in shock
- TSH — thyroid disease associated with PH [18]
- Autoimmune serologies (ANA, anti-Scl-70, anti-centromere) — if connective tissue disease suspected [7][18]
- HIV, hepatitis panel — if risk factors present [7]
- D-dimer — if acute PE suspected
12. Imaging
First-line
- Chest X-ray — enlarged central pulmonary arteries, RV enlargement, RA dilatation; pruning of peripheral vessels [4][7]
- Transthoracic echocardiography — cornerstone of noninvasive evaluation; estimates PA pressure via TR jet velocity; assesses RV size/function (TAPSE, FAC, RV strain), IVC diameter/collapsibility, septal shift [1][6]
Additional imaging
- CT chest with contrast — PA enlargement (PA diameter >29 mm), RV:LV ratio >1, parenchymal lung disease assessment; CT pulmonary angiography if PE suspected [19]
- V/Q scan — to exclude CTEPH (high sensitivity) [7]
- Cardiac MRI — gold standard for RV volumes and ejection fraction; tissue characterization (fibrosis); used when echo quality is poor [6]
When imaging is unnecessary
Gold standard
- Right heart catheterization[7-8][18]
13. Special Tests
- 6-minute walk test (6MWT) — functional capacity assessment, prognosis, and treatment response [20]
- Pulmonary function tests (spirometry, DLCO) — characterize underlying lung disease; low DLCO out of proportion to obstruction suggests pulmonary vascular disease [8][19]
- Cardiopulmonary exercise testing (CPET) — differentiates cardiac vs. ventilatory limitation [19]
- Overnight oximetry / polysomnography — if OSA or OHS suspected [7]
- Vasoreactivity testing during RHC — identifies the small subset of idiopathic PAH patients who respond to CCBs [6]
- Bedside point-of-care ultrasound (POCUS) — rapid ED assessment of RV size, IVC, pericardial effusion [10]
14. ECG
Indications: All patients with suspected cor pulmonale.
Key findings: [6-7][18-19]
- P pulmonale — peaked P wave >2.5 mm in lead II (right atrial enlargement)
- Right axis deviation (QRS axis >90°)
- RV hypertrophy — tall R wave in V1 (R/S >1), deep S in V5–V6
- Right bundle branch block (complete or incomplete) — rSR' in V1
- RV strain pattern — ST depression / T-wave inversion in V1–V4 and inferior leads (II, III, aVF) [19]
- S1Q3T3 — classic for acute cor pulmonale (PE), though sensitivity is low [21]
- Low voltage — may be seen with hyperinflated lungs (COPD)
- Prolonged QTc — nonspecific but associated with PH [19]
In PAH, ECG abnormalities are present in ~87% of patients; right axis deviation (79%), RV hypertrophy (87%), and RV strain (74%) are most common. [18] However, ECG findings are often insensitive in COPD due to hyperinflation. [4]
15. Assessment
Cor pulmonale represents the cardiac consequence of pulmonary disease and carries significant prognostic implications. Key assessment points:
- Acute vs. chronic: Acute cor pulmonale (massive PE, ARDS) presents with sudden hemodynamic collapse; chronic cor pulmonale (COPD, ILD) develops insidiously with progressive RV remodeling [1]
- Severity stratification: Based on functional class (WHO FC I–IV), hemodynamics (mPAP, PVR, cardiac index), biomarkers (BNP/NT-proBNP), 6MWT distance, and imaging (RV function, pericardial effusion) [18]
- Compensated vs. decompensated: Compensated = RV hypertrophy maintaining output; decompensated = RV dilatation, falling cardiac output, systemic congestion [5]
- The development of cor pulmonale in COPD is associated with higher mortality independent of other prognostic variables [4]
- Atypical presentations: Isolated GI symptoms (early satiety, nausea) from hepatic congestion may be the presenting complaint; ankle edema in COPD may reflect RAAS activation rather than true RV failure [19]
16. Treatment Plan
Initial stabilization (acute decompensation)
- Supplemental oxygen — target SpO₂ ≥90%; correct hypoxemia to reduce pulmonary vasoconstriction [2][4]
- Avoid intubation if possible — positive pressure ventilation increases RV afterload; use NIV preferentially [9-10]
- Vasopressors (norepinephrine preferred) for hypotension — NOT large-volume fluid resuscitation [9-10]
- Inotropes (dobutamine or milrinone) for low cardiac output; milrinone with caution due to systemic vasodilation [6]
- Inhaled pulmonary vasodilators (iNO, inhaled epoprostenol) for acute RV failure with elevated afterload [6]
Volume management
- Diuresis with IV loop diuretics for volume-overloaded patients [6]
- Cautious fluid administration — avoid boluses >250 mL; reassess frequently; RV is preload-dependent but easily overloaded [9-10]
Chronic management
- Treat the underlying cause — optimize COPD therapy, treat ILD, anticoagulate CTEPH, address OSA [2]
- Long-term oxygen therapy — for resting PaO₂ ≤55 mmHg or SpO₂ ≤88% [4]
- PAH-specific therapies — combination therapy with ERAs + PDE-5 inhibitors ± prostacyclin analogues for Group 1 PAH; up-front combination is standard of care [6]
- Sotatercept — newer activin signaling inhibitor approved for PAH, shown to improve exercise capacity and reduce clinical worsening events [5][11]
- Surgical options: pulmonary endarterectomy for CTEPH; balloon pulmonary angioplasty for inoperable CTEPH; lung transplantation for refractory cases [6]
- Mechanical circulatory support (ECMO, RVAD) for cardiogenic shock unresponsive to pharmacotherapy; avoid isolated RVAD in severe PAH (risk of pulmonary hemorrhage) [6]
17. Disposition
Admit (ICU) if
- Hemodynamic instability, cardiogenic shock, or need for vasopressors/inotropes
- Acute cor pulmonale (massive PE, acute RV failure)
- Severe hypoxemia refractory to supplemental O₂
- Need for inhaled pulmonary vasodilators or mechanical circulatory support
- New arrhythmias with hemodynamic compromise
Admit (telemetry/step-down) if
- Decompensated chronic cor pulmonale requiring IV diuresis
- New diagnosis of PH requiring workup
- Significant end-organ dysfunction (renal, hepatic)
- Worsening functional status despite outpatient optimization
Observation
Discharge criteria
- Hemodynamically stable on oral medications
- Adequate oxygenation on home O₂ regimen
- Euvolemic or near-euvolemic
- Stable or improving renal function
- Reliable follow-up arranged
Specialist consultation triggers
- Pulmonary hypertension specialist — all new diagnoses; consider transfer to PH center of excellence for advanced therapies [6][9]
- Cardiothoracic surgery — CTEPH evaluation for endarterectomy
- Transplant team — refractory RV failure, advanced PAH
- Palliative care — intractable RV failure with no curative options [6]
18. Follow Up / Return Precautions
Follow-up timing
- Within 7 days of discharge for decompensated cor pulmonale [22]
- PH specialist follow-up within 1–3 months for new diagnoses
- Regular monitoring: BNP, 6MWT, echocardiography at intervals guided by disease severity
Return precautions — instruct patients to seek immediate care for:
- Worsening shortness of breath at rest
- New or worsening leg swelling, abdominal distension
- Syncope or near-syncope
- Chest pain
- Weight gain >2–3 lbs in 24 hours or >5 lbs in a week
- Lightheadedness, confusion, or decreased urine output
Patient counseling
- Daily weight monitoring
- Strict adherence to sodium and fluid restrictions
- Never abruptly discontinue PAH medications — can precipitate fatal RV failure [9]
- Avoid strenuous exertion, Valsalva maneuvers, and high altitude
- Smoking cessation is essential
- Influenza and pneumococcal vaccination
Expected course
- Chronic cor pulmonale is progressive if the underlying cause is not addressed; prognosis depends heavily on the etiology and response to treatment [2][4]
- With appropriate therapy (especially oxygen in COPD, PAH-targeted drugs in Group 1), functional capacity and survival can improve [4][6]
Images
References
1. Cor Pulmonale: The Role of Traditional and Advanced Echocardiography in the Acute and Chronic Settings. — Mandoli GE, Sciaccaluga C, Bandera F, et al. Heart Failure Reviews. 2021.
2. Chronic Cor Pulmonale. Etiology and Management. — Palevsky HI, Fishman AP. The Journal of the American Medical Association. 1990.
3. Cor Pulmonale: An Overview. — Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Seminars in Respiratory and Critical Care Medicine. 2003.
4. Right Ventricular Dysfunction in Chronic Obstructive Pulmonary Disease. Evaluation and Management. — Klinger JR, Hill NS. Chest. 1991.
5. Advanced Molecular, Metabolic, and Imaging Approaches to Characterizing Right Ventricular Failure: A Scientific Statement From the American Heart Association. — Pullamsetti SS, Vanderpool RR, de Man F, et al. Circulation. 2026.
6. Right Ventricular Failure. — Houston BA, Brittain EL, Tedford RJ. The New England Journal of Medicine. 2023.
7. Doppler Trans-Thoracic Echocardiography for Detection of Pulmonary Hypertension in Adults. — Tsujimoto Y, Kumasawa J, Shimizu S, et al. The Cochrane Database of Systematic Reviews. 2022.
8. Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension. — Hoeper MM, Barberà JA, Channick RN, et al. Journal of the American College of Cardiology. 2009.
9. Pulmonary Hypertension and Right Ventricular Failure in Emergency Medicine. — Wilcox SR, Kabrhel C, Channick RN. Annals of Emergency Medicine. 2015.
10. Right Heart Failure: A Narrative Review for Emergency Clinicians. — Kostura M, Smalley C, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.
11. FDA Orange Book. — FDA Orange Book. 2026.
12. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations From the American Society of Echocardiography. — Mukherjee M, Rudski LG, Addetia K, et al. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. 2025.
13. Cor Pulmonale Parvus in Chronic Obstructive Pulmonary Disease and Emphysema: The MESA COPD Study. — Kawut SM, Poor HD, Parikh MA, et al. Journal of the American College of Cardiology. 2014.
14. Pulmonary Hypertension Associated With Lung Disease: New Insights Into Pathomechanisms, Diagnosis, and Management. — Olsson KM, Corte TJ, Kamp JC, et al. The Lancet. Respiratory Medicine. 2023.
15. Differentiation of Constriction and Restriction: Complex Cardiovascular Hemodynamics. — Geske JB, Anavekar NS, Nishimura RA, Oh JK, Gersh BJ. Journal of the American College of Cardiology. 2016.
16. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. — Konstam MA, Kiernan MS, Bernstein D, et al. Circulation. 2018.
17. A Prospective Evaluation of the Diagnostic Accuracy of the Physical Examination for Pulmonary Hypertension. — Braganza M, Shaw J, Solverson K, et al. Chest. 2019.
18. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. — Ruopp NF, Cockrill BA. The Journal of the American Medical Association. 2022.
19. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. — Humbert M, Kovacs G, Hoeper MM, et al. The European Respiratory Journal. 2023.
20. Secondary Pulmonary Hypertension--Diagnosis and Management. — Carbone R, Bossone E, Bottino G, Monselise A, Rubenfire M. European Review for Medical and Pharmacological Sciences. 2006.
21. Relation of Electrocardiographic Changes in Pulmonary Embolism to Right Ventricular Enlargement. — Stein PD, Matta F, Sabra MJ, et al. The American Journal of Cardiology. 2013.
22. Contemporary American And European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison. — Ostrominski JW, DeFilippis EM, Bansal K, et al. JACC. Heart Failure. 2024.